Edesa Biotech (EDSA) Receivables (2013 - 2026)
Edesa Biotech (EDSA) posted Receivables of $431325.0 for Q4 2025, down 32.91% sequentially from $642866.0 in Q3 2025, and up 23.01% YoY from $350639.0 in Q4 2024.
Edesa Biotech (EDSA) Receivables (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Receivables for 13 years, with the latest figure at $431325.0 in Q4 2025.
- Quarterly Receivables rose 23.01% year-over-year to $431325.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $431325.0 (up 23.01% YoY) and the FY2025 annual result came in at $642866.0, up 137.3% from the prior year.
- Receivables eased to $431325.0 in Q4 2025 per EDSA's latest filing, from $642866.0 in the prior quarter.
- Over five years, Receivables peaked at $8.2 million in Q2 2021 and troughed at $42866.0 in Q2 2023.
- A 5-year average of $2.0 million and a median of $634704.5 in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2021 and 2023: Receivables surged 14379.72% in 2021, then tumbled 98.29% in 2023.
- Over 5 years, Receivables stood at $5.5 million in 2021, then sank by 97.72% to $125477.0 in 2022, then surged by 492.59% to $743569.0 in 2023, then plunged by 52.84% to $350639.0 in 2024, then grew by 23.01% to $431325.0 in 2025.
- According to Business Quant data, Receivables over the past three periods registered $431325.0, $642866.0, and $286743.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | 228,051.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 228,051.00 |
| Dec 31, 2025 | 431,325.00 |
| Sep 30, 2025 | 642,866.00 |
| Jun 30, 2025 | 286,743.00 |
| Mar 31, 2025 | 382,440.00 |
| Dec 31, 2024 | 350,639.00 |
| Sep 30, 2024 | 270,908.00 |
| Jun 30, 2024 | 551,064.00 |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | 743,569.00 |
| Sep 30, 2023 | 626,543.00 |
| Jun 30, 2023 | 42,866.00 |
| Mar 31, 2023 | 50,233.00 |
| Dec 31, 2022 | 125,477.00 |
| Sep 30, 2022 | 2.36 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 2.35 Mn |
| Dec 31, 2021 | 5.51 Mn |
| Sep 30, 2021 | 6.33 Mn |
| Jun 30, 2021 | 8.18 Mn |